Apremilast for the treatment of psoriatic arthritis

LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

(2014) A. Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

(2013) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

(2013) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

(2013) W.C. Ports et al.   BRITISH JOURNAL OF DERMATOLOGY

Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses

(2013) Erica D. Dommasch et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses

(2013) Michelle A. Lowes et al.   TRENDS IN IMMUNOLOGY

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

(2013) Andrew Palfreeman et al.   Drug Design Development and Therapy

Ustekinumab Associated With Flares of Psoriatic Arthritis

(2013) Emily F. Stamell et al.   JAMA Dermatology

Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential

(2013) Alice Gottlieb et al.   Therapeutic Advances in Musculoskeletal Disease

Comparative Efficacy of Biologics in Psoriasis

(2012) Iris H. Kim et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

(2012) Georg Schett et al.   ARTHRITIS AND RHEUMATISM

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

(2012) Peter Schafer   BIOCHEMICAL PHARMACOLOGY

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Current investigational drugs in psoriasis

(2012) Caitriona Ryan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

(2012) T. Tzellos et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

(2012) Kim Papp et al.   LANCET

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?

(2011) D. D. Gladman et al.   ANNALS OF THE RHEUMATIC DISEASES

Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study

(2011) W.-Q. Li et al.   BRITISH JOURNAL OF DERMATOLOGY

Recent advances in IL-22 biology

(2011) L. A. Zenewicz et al.   INTERNATIONAL IMMUNOLOGY

Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events

(2011) Caitriona Ryan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response

(2011) Suzanne Tintle et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-17 receptor and its functional significance in psoriatic arthritis

(2011) Siba P. Raychaudhuri et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Disposition, metabolism and mass balance of [14C]apremilast following oral administration

(2011) Matthew Hoffmann et al.   XENOBIOTICA

Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis

(2010) Lisa C. Zaba et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: A ‘class effect’ of TNF-α antagonists or simply an anti-psoriatic treatment adverse reaction?

(2010) Efstathios Rallis et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study

(2010) O. Ahlehoff et al.   JOURNAL OF INTERNAL MEDICINE

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Golimumab

(2009) Vicki Oldfield et al.   BIODRUGS

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

(2009) PH Schafer et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis

(2009) Kerstin Wolk et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

(2009) Hon-Wah Man et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Treatment recommendations for psoriatic arthritis

(2008) C T Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Investigation of association of the IL12B and IL23R genes with psoriatic arthritis

(2008) Charlotte Filer et al.   ARTHRITIS AND RHEUMATISM

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

(2008) A. B. Gottlieb et al.   CURRENT MEDICAL RESEARCH AND OPINION

Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab

(2008) J. Borrás-Blasco et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis

(2008) Sayaka Shibata et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases

(2008) Justin M. Ko et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY